A single-center pilot study evaluating the safety and efficacy of a preemptive short course of glecaprevir/pibrentasvir in hepatitis C positive to negative kidney transplantation

Brief description of study

The purpose of this research study is to evaluate the feasibility of a 2 week course of glecaprevir/pibrentasvir (Mavyret) starting immediately prior to transplantation to treat hepatitis C virus (HCV) in kidney transplant recipients who receive a kidney from a donor with HCV. Mavyret is a combination pill with two medicines (glecaprevir and pibrentasvir) to treat HCV infection. It has been shown to effectively treat HCV Infection in non-transplantation and in transplantation patients with success rates of >98% (more than 98 out of 100). Although Mavyret is approved by the Food and Drug Administration (FDA) for treatment of established HCV infection when taken for 8 weeks, its use in transplant patients for a 2 week duration is not approved, and therefore, is investigational.

Clinical Study Identifier: s20-01386
ClinicalTrials.gov Identifier: NCT04682509

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.